Anti-hypertensive Therapeutics in Asia-Pacific Markets to will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021

ResearchMoz added Latest Research Report titled " Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline " to it's Large Report database.

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=288677

The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate the ACEIs.

Scope

• Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
• Will generics continue to dominate treatment?
• How do the elderly populations and their associated risk factors affect prevalence?
• The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of development, dominated by small molecules.

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Pathophysiology
2.2 Etiology
2.3 Signs and Symptoms
2.4 Co-morbidities and Complications
2.5 Diagnosis
2.5.1 Office or Clinic Blood Pressure Monitoring
2.5.2 Ambulatory Blood Pressure Monitoring
2.5.3 Home Blood Pressure Monitoring
2.5.4 Miscellaneous Methods
2.5.5 Diagnosis of Target Organ Damage
2.5.6 Diagnosis of Hypertension in Pregnancy
2.6 Classification
2.7 Epidemiology
2.8 Prognosis
2.9 Treatment and Management
2.9.1 Treatment Strategy

3 Marketed Products
3.1 Key Marketed Products
3.1.1 Prestalia (perindopril arginine + amlodipine besylate)
3.1.2 Azilva (azilsartan medoxomil)
3.1.3 Amlodipine besylate
3.1.4 Telmisartan
3.1.5 Aliskiren

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG